[Therapy of hyperlipidemia. Clinical experience with clinofibrate].
The results are reported of a double-blind crossover trial intended to evaluate the effectiveness and safety of a new aryloxy derivative compared to placebo. Twenty patients with hyperlipidemia not responding to dietary treatment received either one capsule of the active substance or of placebo (200 mg) three times daily for 16 weeks. Total cholesterol, HDL and triglycerides showed the following changes at the of the treatment period: -11%, +6% and -48% with clinofibrate and -1%, -4% and -1% during control periods. The substance was well tolerated; only in one patient clinofibrate was withdrawn as a precaution in view of the onset of medium severe diarrhea and abdominal pain.
Avellone
G
G
Di Garbo
V
V
Strano
A
A
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006016:Glycolates / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010642:Phenoxyacetates / Q000009:adverse effects / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D006016:Glycolates; D000960:Hypolipidemic Agents; D010642:Phenoxyacetates; D014280:Triglycerides; C006231:clinofibrate; D002784:Cholesterol
Terapia delle iperlipidemie. Esperienza clinica con clinofibrato.